



The Ottawa  
Hospital | L'Hôpital  
d'Ottawa



Carleton  
UNIVERSITY



uOttawa

# How lack of in vivo dosimetry decreases safety and efficiency in brachytherapy

---

**Joanna E. Cygler, Ph.D.**

*The Ottawa Hospital Cancer Centre, Ottawa, Canada*

*Dept. of Physics, Carleton University, Ottawa, Canada*

*Dept. of Radiology, University of Ottawa, Ottawa, Canada*



**AAPM 61<sup>st</sup> Annual Meeting, July 14-18, 2019, San Antonio, Texas**

## Disclosure

---

### Patent for RADPOS Dosimetry System

*A. Saoudi, J.E. Cygler, R.W. Ashton, US Patent 7831016*

2

## Objectives

---

- To present rationale for in vivo dosimetry in brachytherapy
  - increased safety
  - efficiency
- To discuss challenges in clinical implementation of in vivo dosimetry program
- To review currently available commercial systems for on-line in vivo dose measurements


3

## Rationale for in vivo dosimetry in brachytherapy

“To err is human” – *Alexander Pope, An Essay on Criticism, Part II*, 1711


- Errors and dose misadministrations in radiotherapy can result in:
  - Underdosing (geographic miss) of the tumor
  - Overdosing of healthy organs
- Magnitude of errors range
  - from a few percent to lethal doses
  - from a couple of millimeters to complete misses of the tumor
- Many brachytherapy procedures are performed without the safeguards of Record and Verify systems
- In vivo dosimetry is the only way to know what dose was actually delivered to the tumour and organs at risk, OAR

4




### **Safety Reports Series No. 17 (2000)**

30% of cases are incidents in brachytherapy



### **ICRP Publication 97 (2005)**

Prevention of High-Dose-Rate Brachytherapy Accidents




### **ICRP Publication 98 (2005)**

Radiation Safety Aspects of Brachytherapy for Prostate Cancer using Permanently Implanted Sources

5

## Types of errors in brachytherapy

- Equipment errors
  - mechanical errors
  - control unit failure
  - computer
  - source cable
  - applicators
- Procedure problems
- Human errors



*U.S. NRC NUREG-2170 (2017)*

6

## Examples of incidents in HDR brachytherapy related to human errors

- Human errors
  - treatments given to wrong patients
  - incorrectly prescribed / delivered doses or repeated treatments to the same patient.
  - Treatments given to a wrong site (e.g. *wrong orifice treated*)
  - Errors during treatment planning (e.g. *reverse order of entry of dwell positions; applicator diameter confused with radius; wrong dwell steps; wrong catheter length*)

7

## Causes of human errors

---

- Complex, high pressure work environment in brachytherapy
- Combined with how the human brain works



Prospective Memory

8



# Prospective Memory

- Prospective memory involves remembering to perform an action at the appropriate time (*McDaniel & Einstein, 2000*).
- Depends on:
  - How the human brain works
  - Complexity of work environment
- Brachytherapy setting
  - requires multi-tasking
  - frequent interruptions and distractions

9

## Prospective Memory - vulnerability

- Brachytherapy workers carry a particularly high load on their prospective memory
  - risk of errors
- *Eliminating or minimizing the interruptions during procedures could help **to reduce** load on prospective memory and therefore human errors.*
- *In some cases, in vivo dosimetry would have prevented propagation of certain errors to multiple fractions/patients and therefore improve safety and efficiency in brachytherapy.*

10

## Recent (2018) incident in North America: impact on safety and efficiency of brachytherapy process


---

- HDR cervix treatments
  - wrong catheter LENGTH
    - geographic miss of the tumor
    - overdose of healthy tissues
- Investigation
  - 25 patients possibly affected over a period of time
  - patients informed

11

## Negative impact of error on safety and efficiency:

---



12

## Impact on safety and efficiency: Affected Patients

---

- Impact on affected patients – Quality of Life
  - Treatment compromised
    - Failure of tumor control?
    - Overdosed OAR complications?
  - Additional close follow-ups of identified patients
  - Additional diagnostic and pathological tests ordered on periodical basis
  - Emotional impact - anxiety and anger

13

## Impact on safety and efficiency: Prospective Patients

---

- Impact on prospective new cervix patients – Quality of Life
- HDR treatments of future cervix cancer patients suspended till further notice
  - Prospective patients had to travel to other centres
    - Extra cost and inconvenience for these patients

14

## Impact on safety and efficiency: Cancer Centre

---

### Impact on cancer centre

- Extra workload and related cost
  - Close follow-ups of identified patients
  - Additional diagnostic and pathological tests ordered for affected patients on periodical basis
- Suspension of HDR treatments of cervix cancer till further notice
  - Loss of funding for the involved centre
- Reputation

15

## Conclusions / lessons learned

---


There are many lessons learned, but in the context of this lecture:

***Routine, adequate in vivo dosimetry would***

- ***limit the number of patients / tx fractions affected by this error***
- ***Improve safety and efficiency in brachytherapy***

16





ICRP 86 (2000) – “adequate in vivo dosimetry would prevent most of accidental exposures”



17

## What does “adequate” mean?

- Every fraction?
- Once a week?
- First fraction only?

***We need to define what “adequate” means!***

*ESTRO’s basic philosophy includes routine in-vivo dosimetry as an important part in Quality Control of radiotherapy*

*In vivo dosimetry is required by law in some countries*

18

## Routine in vivo dosimetry program in brachytherapy

---

What is needed ?

- Robust dosimetry system
  - small detectors with high S/N ratio
  - minimally intrusive to the patient
  - fast and reliable, real-time dose readout

## Types of detectors used for in vivo dosimetry

---

- TLD
  - OSL
- } off-line (passive) dosimetry
- 
- Diodes
  - MOSFETs
  - PSD
  - RL
- } on-line (real-time) dosimetry

20

## Diode system



- Measures rectum and bladder dose
- A five-diode rectum probe
- Two types of single bladder probes

21

## Advantages and disadvantages of diodes

### Advantages


- High sensitivity(18000× equal volume ion chamber)
- Real time on-line readings
- Efficient (fast) in use
- Waterproof
- Durable

### Disadvantages

- Temperature dependence
- Energy dependence
- Angular dependence
- Different detectors for photon and electron beams
- Radiation damage – change of sensitivity with accumulated dose
- Cumbersome cables on most systems

22

## Mobile MOSFET system



transceiver

Reader / bias box



MOSFET



MOSFET array

*Cygler and Scalchi AAPM  
Summer School 2009*

Two physical detector sizes:

- standard ( $8 \times 2.5 \times 1.3 \text{ mm}^3$ )
- microMOSFETs ( $3.5 \times 1 \times 1 \text{ mm}^3$ )
  - Suitable for brachytherapy



Two detector active volumes (sensitivities):

- Standard ( $0.2 \times 0.2 \times 5 \cdot 10^{-4} \text{ mm}^3$ )
- High ( $0.2 \times 0.2 \times 1 \cdot 10^{-3} \text{ mm}^3$ )

# RADPOS\*

## Time-resolved dosimetry system

- Combination of microMOSFET dosimeter and electromagnetic positioning sensor
- Simultaneous measurements of dose and spatial position
- Software allows sampling dose and position manually/automatically
- Real-time treatment verification tool
  - Patient and/or organ motion
  - Accuracy of delivered dose
- Suitable for brachytherapy



\*RADPOS, A. Saoudi, J.E. Cygler, R.W. Ashton, US Patent 7831016;  
Cherpak et al, Med. Phys. 2009, Med Phys 2011, Radiother. Oncol. 2012



## Advantages and disadvantages of MOSFET detectors

### Advantages

- Instantaneous readouts (on-line dosimetry)
- Very small active volume
- dual detectors eliminate most correction factors
- No temperature dependence for dual-MOSFET-dual-bias
- Waterproof
- Efficient in use (doesn't consume much time)

### Disadvantages

- Finite life expectancy
- Energy dependence
- Some (2.5%) angular dependence
- Temperature dependence for single-MOSFET- single-bias detector

25

## Exradin W1 Plastic Scintillator



Plastic Scintillator Detector, PSD

Physical probe size is 2.8 mm diameter, 42 mm length

Active volume size is 1.0 mm diameter, x 3.0 mm length




<http://www.standardimaging.com/exradin/exradin-scintillator/>


26

## In vivo dosimetry with PSD

- Small size (2.8 mm diameter x 42 mm long)
  - can fit into rectal probe
  - can fit into Foley catheter



Exradin W1 Scintillator  
from Standard Imaging



A detector patch

- The red line represents the dose sensitive region
- Detector elements are spaced every 2 mm



The detectors are mounted on a  
rectal balloon

*Pictures courtesy of S. Beddar*

*Archambault L, et al, Int J Radiat Oncol Biol Phys 78:280-287, 2010.*

27


# Advantages and disadvantages of plastic scintillators

## Advantages

- On-line system
- Spatial resolution
- Linear response to dose
- Dose rate independence
- Energy independence
- Easy to produce
- Relatively inexpensive

## Disadvantages

- Some temperature dependence
- Some radiation damage ( $\sim 2\%$  / kGy)





Wootton and Beddar, PMB 2013

28

## In vivo dosimetry with RL detectors: Securidose -BT

- Based on GaN crystal radioluminescence
- Real-time dosimetry system for HDR
- Developed by the universities of Grenoble (UJF) and Lyon (UCBL) and Dosilab Co
- Miniature crystal fits in a brachytherapy needle



<https://www.dosilab.ch/en-ch/home>

29

## Technical challenges for in vivo dosimetry in brachytherapy

---

- High dose gradients
  - Short treatment distances
  - Energy dependence of detector response
  - Uncertainties on radiation source parameters
  - Shortcomings of dose calculation algorithms
- } large effect of positioning errors

30

## Barriers to routine in vivo dosimetry

- Cost (?)
  - Equipment – lack of fully integrated systems (?)
  - Staff to perform and analyze measurements
- Efficiency - increased treatment and staff time (?)  
**Not true for fully integrated system**
- Staff resistance (?)
  - Lack of well documented guidelines, protocols and procedures (?)
  - Lack of proper training
  - Extra work load
  - Uncertainty about possibly changing work role in the treatment team

31

## Integrated in vivo dosimetry - SagiNova®

### Eases handling of real-time in vivo dosimetry

- Integration of probe connection into treatment delivery unit
- Integrated live monitoring of doses to rectum and bladder at the control console
- Complete data integrated in treatment report
- Warnings displayed if dose limits are exceeded
- Individual definition of dose limits for bladder and rectum



Dosimetry equipment  
of **PTW**

Eckert & Ziegler BEBIG – SagiNova®  
Presentation 2016

[http://www.bebig.com/united\\_states/products/hdr\\_brachytherapy/new\\_saginova/](http://www.bebig.com/united_states/products/hdr_brachytherapy/new_saginova/)

32




# Integrated in vivo dosimetry

[http://www.bebig.com/united\\_states/products/hdr\\_brachytherapy/new\\_saginoval/](http://www.bebig.com/united_states/products/hdr_brachytherapy/new_saginoval/)

## Live monitoring of dose to rectum and bladder including highlighting of high values

Dose Monitoring Displayed on the Control Unit



Diodes for dose measurement in bladder and rectum

Eckert & Ziegler BEBIG – SagiNova®  
Presentation 2016



33

## Conclusions

- Errors in brachytherapy dose delivery do happen
- Human errors account for the largest fraction of all errors
- They can affect multiple tx fractions and/or patients
- Errors have negative impact on safety and efficiency of the brachytherapy process
  - result in compromised treatment outcomes
  - consume extra time and resources
- **Routine in-vivo dosimetry** would prevent propagation of errors to multiple tx fractions and/or patients and therefore **improve safety and efficiency in brachytherapy**
- Commercial in vivo dosimetry systems exist and should be routinely used in brachytherapy

34

## On-line measurements on patients

- Waldhäusl et al, *Radiother.and Onc.* (2005), **77**, 310 (diodes, **55** patients)
- Cygler et al, *Radiother. and Onc.* (2006 ), **80**, 296 (single MOSFET, **5** patients)
- Nose et al, *Int. J. Rad. Onc. Biol. Phys.* (2008 ), **70**, 626 (RPLGD, **66** patients) \*
- Andersen et al, *Med. Phys.* (2009), **36**, 5033 (RL, **5** patients)
- Bloemen-van Gurp et al, *Int. J. Rad. Onc. Biol. Phys.* (2009) **75**,1266 (MOSFET array, **5** patients)
- Suchowerska et al, *Int. J. Rad. Onc. Biol. Phys.* (2011) **79**, 609 (PSD, **24** patients)
- Cherpak et al, *Brachytherapy*, **13**, (2014 )169 (RADPOS, **16** patients)
- Carrara et al, *Radiother.and Onc.* . (2016) **118** 148 (MOSkins,**12** patients)

\**passive (not on-line) detectors*

35

### Selected references

1. P.O. Lopez, P. Andreo, J-M. Cosset, A. Dutreix, T. Landberg, ***“Prevention of accidental exposures to patients undergoing radiation therapy”***. 2000, ICRP Publications 86, Annals of the ICRP. New York, NY: Pergamon
2. G.O. Sawakuchi, L. Archambault, A. Scullion and J.E. Cygler. ***Results of a survey to assess the current status of in-vivo dosimetry in Canada***, Interactions: the Canadian Medical Physics Newsletter, 58 (1), 13-18, 2012
3. J.E. Cygler and P. Scalchi, ***“MOSFET Dosimetry in Radiotherapy”***, in Clinical Dosimetry Measurements in Radiotherapy, American Association of Physicists in Medicine Medical Physics Monograph No. 34, ISBN: 978-1-888340-83-9, Medical Physics Publishing(Madison WI 2009), p.941-977
4. A.J. Cherpak, J.E. Cygler, C.E. G. Perry, ***Real-time measurement of urethral dose and position during permanent seed implantation for prostate brachytherapy***, 2014 Brachytherapy, **13**: 169-177,
5. K. Tanderup, S. Beddar, C.E. Andersen, G. Kertzscher, J.E. Cygler , 2013 Vision 20/20 Article: ***“In vivo dosimetry brachytherapy”***, Med Phys **40**: 070902 (15 pages)
6. B. Mijneer, A. S. Beddar, J. Izewska, and C. S. Reft, 2013 Vision 20/20 Article: ***“In vivo dosimetry in external beam radiotherapy”***, Med. Phys. **40**, 070903 (19 pages.)
7. G. Kertzscher, A. Rosenfeld, S. Beddar, K. Tanderup, J.E. Cygler. ***In vivo dosimetry: trends and prospects for brachytherapy***. Br J Radiol 2014; **87**:20140206. doi: 10.1259/bjr.20140206
8. A. S. Beddar, T. R. Mackie, and F. H. Attix, ***“Water-equivalent plastic scintillation detectors for high-energy beam dosimetry: I. Physical characteristics and theoretical consideration,”*** 1992, Phys. Med. Biol. **37**: 1883–1900.
9. L. Wootton, S. Beddar ***“Temperature dependence of BCF plastic scintillation detectors”***. Phys Med Biol 2013; **58**: 2955–67. doi:10.1088/0031-9155/58/9/2955
10. L. Wootton, R. Kudchadker, A. Lee, S. Beddar, ***“Real-time in vivo rectal wall dosimetry using plastic scintillation detectors for patients with prostate cancer”***. Phys Med Biol 2014; **59**: 647–60. doi: 10.1088/0031-9155/59/3/647

### Selected references cont.

11. M. Soubra, J. Cygler, G. Mackay, "**Evaluation of a dual bias dual metal-oxide-silicon semiconductor field effect transistor detector as radiation dosimeter**", 1994, Med. Phys. **21**: 567-572
12. C. E. Andersen, S. K. Nielsen, S. Greilich, et al, "**Characterization of a fiber-coupled  $Al_2O_3:C$  luminescence dosimetry system for online in vivo dose verification during  $^{192}Ir$  brachytherapy**", 2009, Med. Phys. **36**: 708–718
13. C. E. Andersen et al., "**Time resolved in vivo luminescence dosimetry for online error detection in pulsed dose-rate brachytherapy**" 2009, Med. Phys. **36**, 5033-5043
14. Archambault, T.M. Briere, F. Poenisch, L. Beaulieu, D.Kuban, A. Lee, and S. Beddar, "**Toward a true real-time in-vivo dosimetry system using plastic scintillators**", 2010, Int J Radiat Oncol Biol Phys **78**:280-287,
15. J. Lambert, Y. Yin, D.R. McKenzie, S.H.Law, A. Ralston and N. Suchowerska, "**A prototype scintillation dosimeter customized for small and dynamic megavoltage radiation fields**" 2010, Phys. Med. Biol. **55**: 1115–26
16. G. Kertzscher, C.E. Andersen, K.Tanderup, "**Adaptive error detection for HDR/PDR brachytherapy guidance for decision making during real-time in-vivo point dosimetry**" 2014, Med. Phys **41**: 1–1118
17. R. Wan, et al, "**Implementation of GaN based real-time source position monitoring in HDR brachytherapy**", Rad. Meas. **71** 293-296 (2014)
18. McDaniel M. & Einstein G, "**Strategic and Automatic Processes in Prospective Memory Retrieval: A Multiprocess Framework**", Appl. Cognit. Psychol. **14**: S127-S144 (2000)
19. Wan, R. et al, "**Implementation of GaN based real-time source position monitoring in HDR brachytherapy**" Rad. Meas. **71** 293-296 (2014)

<https://www.americanbrachytherapy.org/resources/for-patients/patient-safety-in-brachytherapy/>

UK GOV, Radiotherapy Errors and Near Misses Data Report, URL: <https://www.gov.uk/government/publications/safer-radiotherapy-error-data-analysis-report>

37

Thank you

